Dantron

Ondansetron

Method of action: Anti-Abstinence, Antiemetic

Treatment option: Acute Nausea And Vomiting, Cancer, Burping, Morning Sickness, Chemotherapy

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dantron

Quick Facts: Dantron (Ondansetron)

Property	Description
Active ingredient	Ondansetron (typically as the Hydrochloride Dihydrate)
Form	Tablets (ODT, film-coated), Oral Solution, Solution for Injection
Pharmacological class	Selective 5-HT3 receptor antagonist
General purpose	Prevention and relief of nausea and vomiting
Origin	Synthetic compound

Dantron: Definition and Core Composition

Dantron is a commercially available medication containing the active pharmaceutical ingredient Ondansetron, a compound used to prevent and alleviate symptoms of nausea and vomiting. Defined as a synthetic, single-ingredient anti-emetic drug, it is noted for its high degree of selectivity in targeting emesis pathways. Its identity is established by the presence of Ondansetron, typically used as Ondansetron Hydrochloride Dihydrate. The formulation may offer distinct features in patient care, such as the inclusion of the orally disintegrating tablet (ODT) form, which is designed to dissolve rapidly without water, a feature intended for use when acute sickness makes swallowing difficult.

Pharmacological Class and Available Forms

This drug is specifically classified as a selective 5-HT3 receptor antagonist. This precise designation indicates that the primary mechanism involves blocking the neurotransmitter serotonin at the specific 5-HT3 receptors found in the gastrointestinal tract and the chemoreceptor trigger zone of the brain. To ensure delivery across varied patient needs, Dantron is manufactured in diverse dosage forms, including traditional tablets, ODTs, oral solutions (syrups), and sterile solutions suitable for parenteral administration (intravenous or intramuscular injection).

General Purpose: Blocking the Sickness Signal

Utilizing its targeted action, the central function of Dantron is to interrupt the specific nervous and chemical signals that lead to the experience of nausea and the physical act of vomiting. By acting as a selective blocker, the medication fulfills its general therapeutic role of preventing or controlling the onset of these symptoms, often in medical settings where severe sickness is anticipated. This level of specificity makes it a choice when targeted anti-emetic action is required.

What side effects are possible with Dantron?

Possible Side Effects and Safety Information

The safety profile of Dantron (Ondansetron) is defined by official regulatory bodies, detailing adverse reactions classified by their expected frequency and the body systems they affect.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized based on their rate of occurrence, ranging from Very Common to Very Rare, according to regulatory standards:

Very Common (Affects ge1 in 10): Headache.
Common (Affects ge1 in 100 to <1 in 10): Constipation, and a sensation of warmth or flushing.
Uncommon (Affects ge1 in 1,000 to <1 in 100): Seizures, involuntary movement disorders (e.g., dystonic reactions), arrhythmias, hypotension, and transient increases in liver function tests.
Rare (Affects ge1 in 10,000 to <1 in 1,000): Immediate hypersensitivity reactions (sometimes severe, including anaphylaxis), and QTc prolongation, which can lead to serious heart rhythm abnormalities like Torsade de Pointes.

Serious Adverse Reactions and Safety Constraints

The official labeling documents highlight risks of serious adverse reactions primarily concerning cardiac safety, specifically QTc prolongation and associated arrhythmias. Serotonin Syndrome is also noted, particularly when the medicine is used concomitantly with other serotonergic agents. Severe hypersensitivity reactions are also documented.

Safety limitations officially documented include a contraindication against simultaneous use with apomorphine due to the risk of profound hypotension. Furthermore, the medicine should be avoided in individuals with a history of congenital long QT syndrome. For patients with moderate or severe hepatic impairment, the body's clearance of the medication is reduced, which is a key safety consideration formally stated in the labeling.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information for Dantron

Dantron (Ondansetron) overdose is defined in regulatory documents based on potential serious manifestations and mandated emergency actions. All overdose management is supportive, as there is no specific antidote known for this medication.

Overdose Manifestations	Severe Risks and Required Actions
Cardiovascular: Hypotension (low blood pressure), transient second-degree AV block, and QTc interval prolongation.	Serotonin Syndrome (reported in overdose cases) and Torsade de Pointes (risk due to QTc prolongation) are life-threatening outcomes.
Neurological: Transient blindness or blurred vision, often resolving within minutes, and symptoms associated with Serotonin Syndrome.	ECG Monitoring is explicitly recommended in all cases of suspected overdose due to cardiac risks.
Gastrointestinal: Severe constipation; monitoring for signs of subacute intestinal obstruction is required.	Symptomatic and supportive therapy is the only established management approach.

When Immediate Medical Help is Required

Official prescribing information mandates that individuals seek immediate medical help if any symptoms indicative of myocardial ischemia occur, such as sudden chest pain or chest tightness. Serotonin Syndrome and severe cardiac symptoms also necessitate immediate emergency care.

Population-Specific Consideration

Cases consistent with Serotonin Syndrome have been specifically reported in infants and young children (aged 12 months to 2 years) following inadvertent oral overdoses that exceeded estimated ingestion limits.

Therapeutic Uses of Dantron

Dantron (Ondansetron) is an anti-emetic medication commonly used to help with symptoms related to physical discomfort, supporting the management of severe nausea and vomiting caused by specific medical triggers. It is applied across domains where additional symptomatic support is needed and is relevant in clinical settings marked by increased discomfort. It is generally used in contexts involving heightened systemic burden where sickness is anticipated or acutely present.

Therapeutic Management of Nausea and Vomiting

It is specifically used for patients undergoing emetogenic cancer chemotherapy, radiation therapy, and surgical procedures requiring general anesthesia, contributing to easing the overall symptom load during and after the procedure. Dantron is applied to address active symptomatic manifestations, including the cessation of acute vomiting episodes and the management of delayed sickness that may follow cancer treatments days later. The central benefit is providing symptomatic relief, which supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.

Quick Fact: Supportive Management for Acute Sickness
Primary Therapeutic Focus: Management of acute and delayed vomiting and nausea.
Core Symptom Clusters: Anticipated sickness, active emesis, and post-treatment delayed sickness.
Benefit: Supports the patient's ability to cope more steadily with difficult episodes and assists with maintaining functional stability.

Regulatory References

NIH DailyMed official drug label

Eligibility and Restrictions for Use

The official regulatory profile for Dantron (Ondansetron) strictly defines the populations who may and may not use the medicine.

Absolute Prohibitions and Contraindications

The medication is contraindicated for any individual with a history of hypersensitivity to Ondansetron or its components. It is also absolutely prohibited for patients who are concurrently receiving apomorphine, based on the documented risk of profound hypotension. Furthermore, use must be avoided in patients diagnosed with congenital long QT syndrome due to the potential for severe cardiac risk.

Age and Established Use

Dantron is approved for use in adults. For pediatric patients, eligibility is established for intravenous administration as young as 1 month for postoperative nausea, and 6 months for chemotherapy-induced nausea. However, the safety and efficacy of oral forms are not established for children younger than four years of age.

Condition-Based Restrictions

Eligibility is restricted for individuals with severe hepatic impairment, requiring a specific regulatory limit on the total maximum daily dose. Conversely, no alteration to the dosing regimen is required for patients with renal impairment. Use during the first trimester of pregnancy is restricted, and caution is recommended during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify the interaction profile of Dantron (Ondansetron) based on pharmacokinetic and pharmacodynamic effects with specific substances, creating mandatory restrictions on co-administration.

Contraindicated Combinations

Co-administration with Apomorphine is strictly prohibited due to the officially documented risk of profound hypotension and loss of consciousness.

Drug–Drug Interaction Patterns

Interaction Type	Interacting Substances/Classes	Official Description of Outcome
Pharmacokinetic (Clearance)	Phenytoin, Carbamazepine, Rifampicin (CYP3A4 Inducers)	Co-administration significantly increases the oral clearance of Dantron, leading to decreased drug exposure.
Pharmacodynamic (Serotonin Risk)	Serotonergic drugs (e.g., SSRIs, SNRIs)	Official post-marketing reports indicate a risk of Serotonin Syndrome when used concomitantly.
Pharmacodynamic (Cardiac Risk)	Medicinal products that prolong the QT interval	Combination use increases the risk of serious cardiac events, such as Torsade de Pointes, due to additive effects.
Pharmacodynamic (Analgesia)	Tramadol	Dantron may potentially reduce the analgesic effect of Tramadol.

Mechanism of Action

Selective Antagonism of the 5-HT3 Receptor

The core mechanism involves the selective antagonism of the serotonin 5-HT3 receptor, a primary molecular target located both peripherally on the vagal afferent nerve terminals in the gut and centrally within the brain's Chemoreceptor Trigger Zone (CTZ). By binding to this receptor without activating it, Ondansetron blocks the ability of endogenous serotonin to transmit signals, modifying an early molecular step that influences the subsequent signaling cascade.

Dual Interruption of the Emetic Cascade

The drug provides a dual-site blockade by simultaneously targeting the signal's origin in the gut and its integration point in the brainstem. This combined action interrupts the vagal afferent signaling pathway and suppresses the central emetic cascade, which reduces the intensity of afferent signaling to the Vomiting Center. This modulation is highly specific, meaning the mechanism is physiologically constrained, exhibiting low affinity for the histaminergic and cholinergic pathways that mediate motion-induced emesis.

Modulation of Visceral Physiology

As a functional consequence of the peripheral action in the enteric nervous system, the drug's mechanism also subtly influences gastrointestinal motility by affecting nerve activity in the gut wall. This leads to a mild slowing of colonic transit time, a predictable physiological adjustment that accompanies the primary mechanism of inhibiting the emetic reflex but is not a prokinetic mechanism.

Dosage and Administration Information

How Dantron (Ondansetron) is Used: Administration Guidelines

Dantron administration is governed by established protocols, specifying the route, dose, and timing based on the clinical context. The medication is available for Oral use (tablets, solution, and Orally Disintegrating Tablets or ODTs) and Parenteral use (Intravenous or Intramuscular injection).

Dosing and Timing Principles

Usage patterns are often pre-emptive, requiring the initial dose to be administered before the anticipated event, such as chemotherapy or surgery. For highly emetogenic chemotherapy, the standard adult oral regimen is a single 24 mg dose taken 30 minutes before the start of treatment. For moderately emetogenic chemotherapy, the oral dosing is typically 8 mg twice daily on subsequent days for up to two days following the initial treatment.

Intravenous administration is generally reserved for hospital settings. For chemotherapy-induced nausea and vomiting (CINV) prevention, IV doses may be 0.15 mg/kg, often administered as an infusion over 15 minutes after dilution. For prevention of postoperative nausea and vomiting (PONV), a single 4 mg IV or IM dose may be given just before anesthesia induction.

Administration Requirements

Orally Disintegrating Tablets (ODTs) are designed to dissolve rapidly on the tongue and do not require water for ingestion, allowing for interchangeability with standard tablets or oral solution at equivalent doses. For patients with severe hepatic impairment (Child-Pugh score ge 10), the total daily dose is constrained and must not exceed 8 mg (oral or intravenous) to account for altered drug clearance.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dantron

Evidence for Use in Chemotherapy-Induced Nausea and Vomiting (CINV)

Research exploring Dantron's use in chemotherapy-induced sickness has primarily used clinical study designs, including Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies were applied in research contexts involving fluctuating or unstable symptoms, specifically aiming to understand the control of emesis (vomiting and retching) and to examine the reported incidence of nausea in patients undergoing cancer treatment. Research was conducted during periods of increased symptom activity—namely, the acute phase (within the first 24 hours of chemotherapy) and the delayed phase (up to five days later).

Findings describe patterns observed in measurements of acute sickness outcomes in patients receiving highly emetogenic chemotherapy. However, long-term effects are not fully established; the follow-up durations were limited, mainly focusing on the immediate days following treatment. The evidence describing long-term, non-chemotherapy-related nausea in cancer patients remains insufficient.

Evidence for Use in Postoperative Nausea and Vomiting (PONV)

Dantron was evaluated in numerous RCTs and systematic reviews for its use in preventing and managing sickness after general anesthesia and surgical procedures. Research examined outcomes related to physical discomfort, such as the total frequency of nausea, vomiting, and retching within the initial 24 hours post-operation. Study populations included a wide range of adults undergoing various surgeries and also included young pediatric patients.

The findings indicate patterns related to the measurement of these acute and disruptive episodes in the immediate recovery phase. The study results described variability in measured outcomes across different surgical types and specific anesthesia protocols that were applied in the trials. Data for long-term outcomes, such as the persistence of mild nausea or extended recovery measures, are still emerging, as most research focused on the immediate postoperative period.

Research on Radiation-Induced Sickness and Other Acute Vomiting Contexts

Dantron was studied for conditions involving periods of heightened symptoms, specifically in patients receiving emetogenic radiation therapy (RINV). Studies monitored outcomes, examining the prevention of nausea and vomiting throughout the entire treatment course. Separately, research has explored the use of a single dose of Dantron in managing vomiting secondary to Acute Gastroenteritis (AGE) in children. Studies measured outcomes such as the need for intravenous (IV) fluids and the completion of oral rehydration therapy (ORT). For RINV, comparative evidence is lacking; research often uses findings extrapolated from CINV studies. Data for continued use in the AGE context remain insufficient.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Dantron (FAQ)

Q: What is Dantron used for?

Dantron is a type of medicine known as a stimulant laxative. It is primarily used for the short-term relief of occasional constipation. Official product information indicates that it works by increasing the activity of the bowel, which helps to move stool through the system.

Q: How quickly does Dantron usually start to work?

According to the official product information, Dantron typically begins to show its effect within 6 to 12 hours after it is taken. Due to this time frame, product information notes that it may be taken at night to allow for an effect the following morning. Specific timing details should be confirmed with the official instructions for use.

Q: Does Dantron interact with other medications?

Regulatory documents state that Dantron can interact with certain other medicines. For instance, it may affect the body's balance of electrolytes, which can be significant when used alongside medicines like digoxin (used for heart conditions). Always consult the official product leaflet for a full list of known interactions.

Q: Is Dantron safe to use during pregnancy or while breastfeeding?

Official information generally advises caution regarding the use of Dantron during pregnancy or breastfeeding. Regulatory documents indicate that the medicine should be avoided unless a doctor specifically considers the potential benefits to outweigh the possible risks. Regulatory warnings indicate that the medicine's components may pass into breast milk.

Q: What should I do if I miss a dose of Dantron?

Since Dantron is typically taken only when needed for occasional constipation, missing a scheduled dose is usually not an issue as it would be for a daily treatment. Official guidance states that managing a missed dose generally means not taking extra to compensate. Follow the advice in the product leaflet or your prescriber's directions.

How should Dantron be stored and disposed of?

Storage and Handling Requirements

Dantron (Ondansetron) must be stored at Controlled Room Temperature, generally 20 C to 25 C (68 F to 77 F), with protection from light and moisture. The medicine must be kept in its original container and maintained tightly closed.

Specific handling rules apply: the injectable solution must not be frozen, and the oral solution should not be refrigerated. Orally Disintegrating Tablets (ODTs) must remain sealed in their blister packaging until the time of use. The official label requires that the medicine be stored out of the sight and reach of children.

Stability and Disposal

The oral solution has a specific shelf-life after first opening and must be discarded within the period noted on the product label (e.g., 45 days). Unused or expired Dantron must be disposed of according to local regulations. Official guidance recommends using a drug take-back program and advises against disposal via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.